Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2


Studies have shown that Tissue Inhibitor of Metalloproteinases 2 (TIMP-2) suppresses tumor growth and tumor-associated angiogenesis. Currently, the main obstacle in using TIMP-2 as a biologic therapeutic has been the inability to produce sufficient quantities of the protein for testing and development. 
NCI Radiation Oncology Branch (ROB) researchers have developed a unique HEK-293F cell line that stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases. Importantly, this inventive cell line can also be produced in great quantities using good laboratory practice (GLP) manufacturing. 



Potential Commercial Applications: Competitive Advantages:

Therapeutic Use
• Use as a biological suppressor of tumor growth, vascular proliferation, and neurodegeneration
Drug Discovery
• Enhance public health by providing a method for production scale, good laboratory practice (GLP) manufacturing of biologic therapies for cancer, ischemic diseases, and neurodegenerative diseases treatment

 

o This is the first time TIMP-2 can be produced in quantities sufficient for testing and development as a novel biologic therapeutic for the treatment of cancer, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases.



Development Stage:
Pre-clinical (in vivo)

Inventors:

William Stetler-Stevenson (NCI)  ➽ more inventions...

Beiyang Wei (NCI)  ➽ more inventions...


Intellectual Property:

Publications:
Ananda Chowdhury, et al. Recombinant human Tissue Inhibitor of Metalloprotease‐2; a novel anti‐cancer therapeutic. DOI 10.1096/fasebj.31.1_supplement.823.10

Collaboration Opportunity:

Licensing only


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-216-2017
Updated: Dec 4, 2017